What is Pharmacogenomics?

Pharmacogenomics (or PGx) is the study of genetic variations that influence responses to healthcare medications. Pharmacogenomic testing enables doctors and healthcare professionals to test for specific genetic changes and predict whether a patient may have a normal or poor response, or a higher risk of side effects, before prescribing a specific medication.

PGx is in our DNA

black and white photo of myDNA Co-founder Associate Professor Les Sheffield

Associate Professor Les Sheffield

Clinical Geneticist & myDNA Co-Founder

Since the 1980s Professor Sheffield has been involved in the design and development of genetic tests. As a Clinical Geneticist, he has authored more than 100 scientific publications. In 2007 he founded myDNA to assist in more informed prescribing of medications. He continues to drive the development of new healthcare services as Medical Director.

Pharmacogenomics has long term healthcare benefits

Reduce the risk of adverse drug reactions
Reduce trial-and-error when prescribing
Offer a personalised healthcare service
Results have a lifetime relevance
Reduce wasted cost on ineffective medication
Fast-track treatment goals

What do we offer?

The myDNA Medication tests use PGx to identify variations in a number of genes that influence responses to medications and healthcare treatments.

We concentrate on the genes encoding the metabolising enzymes (i.e. CYP450 enzymes) which are found mainly in the liver and the gut wall. These genetic variations predict the level of enzyme activity which in turn results in increased or decreased plasma concentrations and drug exposure.

Increased plasma concentrations, due to reduced enzyme activity, can lead to adverse effects. Reduced plasma concentrations, due to increased enzyme activity, can lead to poor therapeutic response.

We offer a multiple medications test, which covers multiple medication categories (currently in excess of over 80 medications). However, if a specific category is more suitable, we also offer single category medication reports.

Mental Health
Pain
Oncology
Gastrointestinal
Cardiovascular

PGx Healthcare in practice

Don’t waste time with trial-and-error

a diagram showing 1 in 5 people
1 in 5 Australians

Suffer from persistent pain, making their risk of depression 4x higher than those without pain1.

a diagram showing 1 in 2 people
50% of patients

Respond to the initial treatment with antidepressants2.

a diagram showing 1 in 10 people
1 in 10 people

May process certain medications too slowly, increasing their risk of side effects3.

a diagram showing 1 in 3 people
1 in 3 people

May process certain medications too quickly, increasing their risk of treatment failure3.

Patients most likely to benefit from our insights:

Those experiencing side effects to specific medications

Anyone not responding to specific medications

Patients requiring doses of specific medications outside the recommended range

Patients planning to start on a new medication covered by the myDNA test

Anyone taking multiple medications

  1. Painaustralia
  2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.
  3. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44.

Mental health research conducted by myDNA

Mental healthcare inadequate for two thirds

Not everybody absorbs medications the same way. 50% of Australians have experienced a mental health issue in their lifetime, and nearly two-thirds believe their mental health treatment could be improved. myDNA can help alleviate the trial-and-error aspect of finding the right dose and ensure patients are taking both safe and effective doses.

a circular slider showing 50%
50% of Australians have experienced a mental health issue in their lifetime
a circular slider showing 66%
Two thirds believe their mental health treatment could be improved
a circular slider showing 20%
One fifth believe they are not on the right drug or dose

How our medications test can change lives

Want to learn more?

Evidence behind pharmacogenomic testing

We reference the guidelines of the Royal Dutch Pharmacists Association, Pharmacogenetics Pharmacogenomics Working Group & the Clinical Pharmacogenetics Implementation Consortium (CPIC), which have been most recently published.

The following publications contain significant evidence for gene-drug associations of which dosage adjustments have been recommended.

  1. CPIC Guideline for CYP2D6 and CYP2C19 genotypes and dosing of Tricyclic Antidepressants
  2. CPIC Guideline for CYP2D6 and CYP2C19 genotypes and dosing of Selective Serotonin Reuptake Inhibitors (SSRIs)
  3. Dutch Pharmacogenetics Working Group guidelines which include a number of antidepressant and antipsychotic medications

Our scientific partner network

Healius Logo
BC Platforms Logo
Illumina Logo
Dorevitch Pathology Logo
Laverty Pathology Logo
Western Diagnostic Pathology Logo
Genomic Diagnostics Logo
QML Pathology Logo
TML Pathology Logo
Abbott Pathology Logo
Australian Clinical Labs Logo
Melbourne Health Logo
Peter MacCullum Logo
Bumrungrad Logo
British Columbia Pharmacy Association Logo
Royal Children's Hospital Melbourne Logo
Ventures Gx Logo

A growing global network with the flexibility to scale and customise accordingly

a stylized world map showing myDNA global operations locations

AUSTRALIA | NEW ZEALAND | USA | CANADA | UK | INDONESIA | SINGAPORE | THAILAND | PHILIPPINES | VIETNAM | BANGLADESH

Trusted accreditation on a global scale

NATA Logo
Global Alliance for Genomics & Health Logo
Department of Health Therapeutic Goods Administration Logo
FDA Logo
Medicines & Healthcare Products Regulatory Agency Logo
Health Canada Logo
Medsafe Logo

Your data under lock and key

Your DNA sample and data remain your property, are stored on secure encrypted services, can be destroyed anytime at your request, and will never be shared without your consent.

Our analysis is limited to the DNA markers we report on. Your results won’t include diseases, can’t be used to identify you, nor will they have any bearing towards insurance policies.

Enquire about genomic reporting for your business

Leave your details below and our partnership team will be in touch.